The 2018 Vanderlaan et al. publication remains one of the most insightful summaries of biopharma’s experience with host cell proteins (HCPs). It includes a case study on MCP-1—an HCP linked to adverse events—that underscores why accurate detection, monitoring, and clearance during process development are critical to product safety. Essential reading for scientists, process developers, and anyone working in HCP analysis.
HCP Spotlight: Understanding MCP-1 in Biologics
Shopping Cart